Want to see BOLT full AI Analyst Report?
BOLT Stock Chart & Stats
$3.83
$0.14(3.77%)
At close: 4:00 PM EDT
$3.83
$0.14(3.77%)
Day’s Range― - ―
52-Week Range$3.13 - $7.20
Previous Close$4
Volume2.84K
Average Volume (3M)29.18K
Market Cap
$7.06M
Enterprise Value$10.33
Total Cash (Recent Filing)$17.60M
Total Debt (Recent Filing)$21.62M
Price to Earnings (P/E)―
Beta0.37
Next Earnings
Nov 05, 2026EPS Estimate
-3.52Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-16.00
Shares Outstanding1,926,345
10 Day Avg. Volume31,146
30 Day Avg. Volume29,181
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.39
Price to Sales (P/S)1.33
P/FCF Ratio-0.26
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$14.50Price Target Upside278.59% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-15.88
Revenue Forecast (FY)$1.13M
Bulls Say, Bears Say
Bulls Say
Strong Gross MarginA roughly 95.7% gross margin indicates substantial profitability on revenue before operating costs. This provides a favorable unit-economics base, although it has not yet offset Bolt’s significant research, development, and other operating expenses.
Narrowing Loss TrendThe multi-year reduction in losses suggests some progress in controlling the cost base and improving operating discipline. This could become a durable advantage for a clinical biotech, but progress remains incomplete because current net losses are still substantial.
Proprietary Immuno-Oncology PlatformBoltbody gives Bolt a differentiated approach to developing immuno-oncology therapies by targeting immune stimulation within tumors. If clinical testing validates the approach, the platform could support a repeatable pipeline and future partnering opportunities.
Bears Say
Revenue Decline And Deep LossesShrinking revenue combined with a large loss on a very small revenue base shows that Bolt has not established commercial scale. Continued operating losses could limit investment capacity and increase reliance on financing before products reach meaningful commercialization.
Persistent Cash BurnSustained cash outflows mean Bolt cannot currently fund operations through internally generated cash. Dependence on external financing creates dilution or refinancing risk and may constrain clinical development if capital markets or partnership funding become less available.
Elevated Balance-Sheet LeverageDebt exceeding equity, alongside a declining asset base and persistent losses, reduces financial flexibility. If operating losses continue, Bolt may need additional financing while carrying greater obligations, increasing balance-sheet risk during clinical development.
Bolt Biotherapeutics News
BOLT FAQ
What was Bolt Biotherapeutics’s price range in the past 12 months?
Bolt Biotherapeutics lowest stock price was $3.13 and its highest was $7.20 in the past 12 months.
What is Bolt Biotherapeutics’s market cap?
Bolt Biotherapeutics’s market cap is $7.06M.
When is Bolt Biotherapeutics’s upcoming earnings report date?
Bolt Biotherapeutics’s upcoming earnings report date is Nov 05, 2026 which is in 74 days.
How were Bolt Biotherapeutics’s earnings last quarter?
Bolt Biotherapeutics released its earnings results on Aug 11, 2026. The company reported -$4.57 earnings per share for the quarter, missing the consensus estimate of -$3.387 by -$1.183.
Is Bolt Biotherapeutics overvalued?
According to Wall Street analysts Bolt Biotherapeutics’s price is currently Undervalued.
Does Bolt Biotherapeutics pay dividends?
Bolt Biotherapeutics pays a Quarterly dividend of $0.09 which represents an annual dividend yield of N/A. See more information on Bolt Biotherapeutics dividends here
What is Bolt Biotherapeutics’s EPS estimate?
Bolt Biotherapeutics’s EPS estimate is -3.52.
How many shares outstanding does Bolt Biotherapeutics have?
Bolt Biotherapeutics has 1,926,345 shares outstanding.
What happened to Bolt Biotherapeutics’s price movement after its last earnings report?
Bolt Biotherapeutics reported an EPS of -$4.57 in its last earnings report, missing expectations of -$3.387. Following the earnings report the stock price went down -13.317%.
Which hedge fund is a major shareholder of Bolt Biotherapeutics?
Currently, no hedge funds are holding shares in BOLT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bolt Biotherapeutics
Bolt Biotherapeutics, Inc. is a biotechnology company currently conducting clinical trials, focused on developing innovative immuno-oncology therapies. Its mission is to create agents that equip the body's immune system to identify and eliminate cancerous cells. A key therapeutic in its pipeline is BDC-1001, an investigational treatment targeting the human epidermal growth factor receptor 2 (HER2). This compound is presently undergoing Phase I/II clinical evaluation for patients with HER2-positive solid tumors, including those exhibiting low HER2 expression. Beyond BDC-1001, the company is advancing several other programs: BDC-2034, which targets carcinoembryonic antigen for various indications such as colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody designed to reprogram crucial immune cells within the tumor microenvironment by interacting with macrophage cell-surface receptors. Bolt is also pursuing a programmed cell death-ligand 1 (PD-L1) initiative aimed at addressing tumors that prove resistant to existing immune checkpoint blockades. Incorporated in 2015 under its previous name, Bolt Therapeutics, Inc., before officially becoming Bolt Biotherapeutics, Inc. in July of the same year, the company maintains its corporate headquarters in Redwood City, California.
BOLT Stock 12 Month Forecast
Average Price Target
$14.50
▲(278.59% Upside)
Technical Analysis
Ownership Overview
2.28% Insiders
3.96% Mutual Funds
20.46% Other Institutional Investors
72.94% Public Companies and
Individual Investors